MCM2 and prostate carcinoma: Notably, in the same prostate cancer patient databases as those in Figure 1, the higher mRNA expression of CCNB1 was observed in the patients with hormone refractory compared to that in the patients having hormone naïve prostate cancer (Figure 9A), and the mRNA expression levels of CCNB1 (Figure 9B), MCM2 (Figure 9C and 9D), PLK1 (Figure 9E and 9F) and AURKB (Figure 9G and 9H) were also increased in patients with metastatic prostate tumors compared to those in patients with primary prostate tumors.